EGFR and non-small cell lung carcinoma: The early randomized phase 2 study of CTONG1103 showed that neoadjuvant erlotinib is more effective than neoadjuvant chemotherapy in EGFR-positive patients with stage IIIA-N2 NSCLC (14).